Evofem Biosciences Stock Net Income
| EVFM Stock | USD 0.01 0.00 0.00% |
As of the 15th of February 2026, Evofem Biosciences shows the Coefficient Of Variation of 2615.47, mean deviation of 4.61, and Downside Deviation of 12.36. Evofem Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Evofem Biosciences coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Evofem Biosciences is priced favorably, providing market reflects its regular price of 0.009 per share. As Evofem Biosciences appears to be a penny stock we also advise to verify its total risk alpha numbers.
Evofem Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Evofem Biosciences' valuation are provided below:Evofem Biosciences does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Evofem |
Evofem Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Evofem Biosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Evofem Biosciences.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Evofem Biosciences on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Evofem Biosciences or generate 0.0% return on investment in Evofem Biosciences over 90 days. Evofem Biosciences is related to or competes with Unidoc Health, and Devonian Health. Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet nee... More
Evofem Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Evofem Biosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Evofem Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 12.36 | |||
| Information Ratio | 0.0294 | |||
| Maximum Drawdown | 48.18 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 11.11 |
Evofem Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evofem Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Evofem Biosciences' standard deviation. In reality, there are many statistical measures that can use Evofem Biosciences historical prices to predict the future Evofem Biosciences' volatility.| Risk Adjusted Performance | 0.0398 | |||
| Jensen Alpha | 0.2179 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0189 | |||
| Treynor Ratio | 0.2325 |
Evofem Biosciences February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0398 | |||
| Market Risk Adjusted Performance | 0.2425 | |||
| Mean Deviation | 4.61 | |||
| Semi Deviation | 5.6 | |||
| Downside Deviation | 12.36 | |||
| Coefficient Of Variation | 2615.47 | |||
| Standard Deviation | 7.94 | |||
| Variance | 63.04 | |||
| Information Ratio | 0.0294 | |||
| Jensen Alpha | 0.2179 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0189 | |||
| Treynor Ratio | 0.2325 | |||
| Maximum Drawdown | 48.18 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 11.11 | |||
| Downside Variance | 152.73 | |||
| Semi Variance | 31.39 | |||
| Expected Short fall | (12.98) | |||
| Skewness | 0.648 | |||
| Kurtosis | 2.83 |
Evofem Biosciences Backtested Returns
Evofem Biosciences appears to be out of control, given 3 months investment horizon. Evofem Biosciences secures Sharpe Ratio (or Efficiency) of 0.0371, which denotes the company had a 0.0371 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Evofem Biosciences, which you can use to evaluate the volatility of the firm. Please utilize Evofem Biosciences' Mean Deviation of 4.61, coefficient of variation of 2615.47, and Downside Deviation of 12.36 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Evofem Biosciences holds a performance score of 2. The firm shows a Beta (market volatility) of 1.26, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evofem Biosciences will likely underperform. Please check Evofem Biosciences' treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Evofem Biosciences' price patterns will revert.
Auto-correlation | 0.13 |
Insignificant predictability
Evofem Biosciences has insignificant predictability. Overlapping area represents the amount of predictability between Evofem Biosciences time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Evofem Biosciences price movement. The serial correlation of 0.13 indicates that less than 13.0% of current Evofem Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.13 | |
| Spearman Rank Test | 0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Evofem Biosciences reported net income of (205.19 Million). This is 160.12% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 135.94% higher than that of the company.
Evofem Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in net income category among its peers.
Evofem Fundamentals
| Return On Equity | -3.87 | |||
| Return On Asset | -1.25 | |||
| Operating Margin | (5.41) % | |||
| Current Valuation | 112.69 M | |||
| Shares Outstanding | 121.22 M | |||
| Shares Owned By Insiders | 0.28 % | |||
| Shares Owned By Institutions | 0.57 % | |||
| Number Of Shares Shorted | 8.68 M | |||
| Price To Earning | (1.26) X | |||
| Price To Book | 8.37 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 8.24 M | |||
| Gross Profit | 4.19 M | |||
| EBITDA | (204.14 M) | |||
| Net Income | (205.19 M) | |||
| Cash And Equivalents | 19.89 M | |||
| Cash Per Share | 0.23 X | |||
| Total Debt | 125.74 M | |||
| Debt To Equity | 8.72 % | |||
| Current Ratio | 0.16 X | |||
| Book Value Per Share | (0.77) X | |||
| Cash Flow From Operations | (146.67 M) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (19.01) X | |||
| Target Price | 2.9 | |||
| Number Of Employees | 119 | |||
| Beta | -1.25 | |||
| Market Capitalization | 6.41 M | |||
| Total Asset | 42.51 M | |||
| Retained Earnings | (526.68 M) | |||
| Working Capital | 3.78 M | |||
| Current Asset | 16.39 M | |||
| Current Liabilities | 12.61 M | |||
| Z Score | -30.0 | |||
| Net Asset | 42.51 M |
About Evofem Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evofem Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evofem Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evofem Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Evofem Pink Sheet
Evofem Biosciences financial ratios help investors to determine whether Evofem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evofem with respect to the benefits of owning Evofem Biosciences security.